Avadel Pharmaceuticals PLC (AVDL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Avadel Pharmaceuticals PLC (AVDL) has a cash flow conversion efficiency ratio of 0.237x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($23.26 Million) by net assets ($98.22 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see AVDL market cap overview for the company's overall valuation and market capitalisation.
Avadel Pharmaceuticals PLC - Cash Flow Conversion Efficiency Trend (1996–2024)
This chart illustrates how Avadel Pharmaceuticals PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Avadel Pharmaceuticals PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Avadel Pharmaceuticals PLC ranked by their cash flow conversion efficiency. Explore cash flow quality index of Avadel Pharmaceuticals PLC to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Stora Enso Oyj A
HE:STEAV
|
0.007x |
|
Íslandsbanki hf.
IC:ISB
|
0.079x |
|
Carborundum Universal Limited
NSE:CARBORUNIV
|
0.029x |
|
Flywire Corp
NASDAQ:FLYW
|
0.026x |
|
GKG Precision Machine Co. Ltd. A
SHE:301338
|
-0.015x |
|
Quick Intelligent Equipment Co Ltd
SHG:603203
|
0.036x |
|
Hunan Aihua Group Co Ltd
SHG:603989
|
0.025x |
|
Aguas Andinas S.A
SN:AGUAS-A
|
0.049x |
Annual Cash Flow Conversion Efficiency for Avadel Pharmaceuticals PLC (1996–2024)
The table below shows the annual cash flow conversion efficiency of Avadel Pharmaceuticals PLC from 1996 to 2024. View Avadel Pharmaceuticals PLC stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $73.85 Million | $-46.91 Million | -0.635x | +56.63% |
| 2023-12-31 | $87.74 Million | $-128.51 Million | -1.465x | -144.05% |
| 2022-12-31 | $-21.14 Million | $-70.30 Million | 3.325x | +436.50% |
| 2021-12-31 | $78.24 Million | $-77.31 Million | -0.988x | -228.99% |
| 2020-12-31 | $162.27 Million | $-48.73 Million | -0.300x | -122.88% |
| 2019-12-31 | $-29.20 Million | $-38.33 Million | 1.313x | +104.41% |
| 2018-12-31 | $2.78 Million | $-82.72 Million | -29.754x | -15200.73% |
| 2017-12-31 | $84.56 Million | $16.66 Million | 0.197x | -56.14% |
| 2016-12-31 | $42.07 Million | $18.90 Million | 0.449x | -63.83% |
| 2015-12-31 | $67.86 Million | $84.29 Million | 1.242x | +391.22% |
| 2014-12-31 | $24.89 Million | $-10.62 Million | -0.427x | -119.62% |
| 2013-12-31 | $-9.51 Million | $-20.68 Million | 2.174x | +386.55% |
| 2012-12-31 | $30.50 Million | $-23.14 Million | -0.759x | -118.93% |
| 2011-12-31 | $29.79 Million | $-10.32 Million | -0.346x | -130.51% |
| 2010-12-31 | $36.30 Million | $-5.46 Million | -0.150x | -182.29% |
| 2009-12-31 | $44.86 Million | $8.20 Million | 0.183x | +218.11% |
| 2008-12-31 | $48.55 Million | $-7.51 Million | -0.155x | +56.09% |
| 2007-12-31 | $54.63 Million | $-19.24 Million | -0.352x | +13.76% |
| 2006-12-31 | $73.03 Million | $-29.83 Million | -0.408x | -82.54% |
| 2005-12-31 | $86.65 Million | $-19.39 Million | -0.224x | -529.51% |
| 2004-12-31 | $116.76 Million | $-4.15 Million | -0.036x | -126.76% |
| 2003-12-31 | $92.06 Million | $12.23 Million | 0.133x | -81.40% |
| 2002-12-31 | $12.29 Million | $8.77 Million | 0.714x | +292.55% |
| 2001-12-31 | $7.51 Million | $-2.78 Million | -0.371x | +28.24% |
| 2000-12-31 | $10.88 Million | $-5.62 Million | -0.517x | -10.51% |
| 1999-12-31 | $9.07 Million | $-4.24 Million | -0.468x | -1.55% |
| 1998-12-31 | $17.79 Million | $-8.19 Million | -0.460x | +26.03% |
| 1997-12-31 | $14.30 Million | $-8.90 Million | -0.622x | -242.31% |
| 1996-12-31 | $23.10 Million | $-4.20 Million | -0.182x | -- |
About Avadel Pharmaceuticals PLC
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name… Read more